Effects of rosuvastatin on atrial fibrillation occurrence: Ancillary results of the GISSI-HF trial

Aldo P. Maggioni, Gianna Fabbri, Donata Lucci, Roberto Marchioli, Maria Grazia Franzosi, Roberto Latini, Gian Luigi Nicolosi, Maurizio Porcu, Franco Cosmi, Severo Stefanelli, Gianni Tognoni, Luigi Tavazzi

Research output: Contribution to journalArticlepeer-review


Aims This ancillary analysis of the GISSI-HF database aims at assessing the effect of rosuvastatin on the occurrence of atrial fibrillation (AF) in patients with chronic heart failure (HF) who were not in AF at study entry.Methods and resultsGISSI-HF was a double-blind, placebo-controlled trial testing n-3 PUFA and rosuvastatin vs. corresponding placebos in patients with chronic HF. Atrial fibrillation occurrence was defined as the presence of AF in the electrocardiogram (ECG) performed at each visit during the trial or AF as a cause of worsening HF or hospital admission or as an event during hospitalization. Among the 3690 patients (80.7%) without AF on their baseline ECG, 15.0% developed AF during a median follow-up period of 3.7 years, 258 randomized to rosuvastatin (13.9%) vs. 294 allocated to placebo (16.0%). Although the difference was not significant at unadjusted analysis (P = 0.097) and multivariable analysis adjusting for clinical variables (P = 0.067), it became significant after adjustment for clinical variables and laboratory examinations (P = 0.039), and for clinical variables, laboratory examinations, and background therapies (P = 0.038).ConclusionThis study shows that there is some evidence of a beneficial effect of rosuvastatin in terms of reduction of AF occurrence in patients with HF. Larger populations are needed to provide a definite answer to the question.ClinicalTrials.gov Identifier: NCT00336336.

Original languageEnglish
Pages (from-to)2327-2336
Number of pages10
JournalEuropean Heart Journal
Issue number19
Publication statusPublished - Oct 2009


  • Atrial fibrillation
  • Heart failure
  • Rosuvastatin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Effects of rosuvastatin on atrial fibrillation occurrence: Ancillary results of the GISSI-HF trial'. Together they form a unique fingerprint.

Cite this